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Background: Small cell carcinoma (SCC) is a rare variant of head and neck cancer characterized by a high-grade
neuroendocrine cancer with similar features to small cell lung carcinoma (SCLC). Human papillomavirus (HPV) is an
increasingly recognized cause of head and neck cancer but usually associated squamous cell carcinoma of the
oropharynx. In this report, we present the clinical presentation, diagnosis, and management of a patient with HPV-related
SCC of the oropharynx that responded favorably to chemotherapy with cisplatin plus etoposide and concomitant
radiation therapy, a regimen typically used in SCLC.
Case presentation: We present a rare case of a 56-year-old man who presented with a three-month history of an
enlarging left-sided neck mass. Imaging was consistent with a soft tissue density at the left tongue base, left level IIB
nodal conglomerate, and multiple bilateral cervical lymph nodes, without evidence of distant metastasis. The patient
underwent a core biopsy of the left neck level II node which read as a poorly differentiated neuroendocrine carcinoma
consistent with small cell carcinoma. Polymerase chain reaction revealed that the tumor was positive for HPV16. The
tumor was staged T1N2cM0 (stage IVA). He went on to receive four cycles of cisplatin and etoposide. On cycle two, he
started radiotherapy to the oropharynx and involved neck nodes. He received a dose of 70 Gray (2 Gy/fraction) over a
seven week-period. During the concomitant phase of chemo-radiation, the patient experienced grade IV mucositis,
grade II nausea, and dehydration for which he received additional outpatient fluid and electrolyte replacement. Three
months after completion of therapy, a PET/CT showed complete resolution of the tumor and metastatic lymph nodes
along with no evidence of distant metastasis.
Conclusion: Patients with HPV-related cancer of the oropharynx require identification of the small cell variant to
optimize therapy and improve outcomes.
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Small cell carcinoma (SCC) is a rare variant of head and
neck cancer characterized by a high-grade neuroendocrine
cancer with similar features to small cell lung carcinoma
(SCLC). The most common location of head and neck
SCC is the larynx, but it has also been reported in the
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HPV-associated oropharyngeal squamous cell carcinoma
(OPSqCC) being the most common variant. Although
HPV positivity is a favorable prognostic factor in
OPSqCC, HPV-related SCC of the oropharynx may share
the same aggressive clinical features of SCLC [2]. In this
report, we present a case of HPV-related SCC of the oro-
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A 56-year-old man with no history of tobacco use or alco-
hol consumption presented with a three-month history of
an enlarging left-sided neck mass and worsening head-
aches. A positron emission tomography/computed tomog-
raphy (PET/CT) showed an [18 F]fluorodeoxyglucose
FDG-avid soft tissue density at the left tongue base meas-
uring approximately 1.8 × 2 cm, a centrally hypodense hy-
permetabolic left level IIB nodal conglomerate measuring
3.6 × 4 cm, and multiple bilateral hypermetabolic cervical
lymph nodes, without evidence of distant metastasis. Brain
MRI was negative for brain metastasis.
The patient underwent a core biopsy of the left neck
level II node which read as a poorly differentiated neuro-
endocrine carcinoma consistent with small cell carcinoma.
Core biopsy of the left neck level II node revealed
sheets of malignant cells with small to intermediate-
sized nuclei, indistinct nucleoli, and scant cytoplasm
consistent with SCC. The tumor exhibited areas of ne-
crosis as well as abundant mitotic figures and apoptotic
bodies. The neoplastic cells were positive for cytokeratin
AE1/AE3, synaptophysin, p16, and TTF-1 with a nucleara
c
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Fig. 1 a Hematoxylin and Eosin tumor stain. b Synaptophysin tumor stain.staining pattern; they were negative for cytokeratin 5/6,
CAM 5.2, p63, chromogranin, CD56, and EBV (by in-
situ hybridization) (Fig. 1).
The tumor was positive for p16, but the combined
morphologic and immunophenotypic features argued
against conventional HPV-associated OPSqCC. Polymer-
ase chain reaction demonstrated that the tumor was
positive for HPV16, negative for HPV18, 31, 33, 35, 39,
45, 51, 52, 56, 59, 66, and 68.
The tumor was staged T1N2cM0 (stage IVA). A per-
cutaneous endoscopic gastrostomy tube (PEG) was
placed before the beginning of treatment to meet his nu-
tritional and hydration needs during treatment. He re-
ceived four cycles of chemotherapy at 21 day-intervals.
The chemotherapy regimen consisted of cisplatin
75 mg/m2 on day one and etoposide 80 mg/m2 on days
one to three. On cycle two, day eight, he started radio-
therapy to the oropharynx and involved neck nodes. He
received a dose of 70 Gray (2 Gy/fraction) over a seven
week-period. During the concomitant phase of chemo-
radiation, the patient experienced grade IV mucositis,
grade II nausea, and dehydration for which he receivedb
d
c TTF-1 tumor stain. d Cytokeratin 5/6 stain. e P63 tumor stain
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Due to grade III neutropenia, the dose of cisplatin and
etoposide was reduced by 25% during the last cycle of
chemotherapy.
Three months after completion of therapy, a PET/CT
showed complete resolution of the tumor and metastatic
lymph nodes along with and no evidence of distant me-
tastasis (Fig. 2). He also had complete resolution of his
mucositis and was able to resume a full oral diet result-
ing in removal of the PEG tube.
Discussion and conclusions
Small cell lung cancer is distinguished by its rapid doub-
ling time, high growth fraction, and early development
of widespread metastases. Although highly responsive to
chemotherapy and radiation initially, the majority of pa-
tients will eventually relapse with broadly resistant dis-
ease a few months to a year from initial therapy. SCLC
occurs almost exclusively in smokers and appears to be
most common in heavy smokers. Historically, SCLC has
been rare in non-smokers, representing just 2.9% of lung
cancer cases in women and none in men as reported in
a case control series [3].
High risk HPV, particularly the 16 type, has been
established as a causative agent for a significant propor-
tion of OPSqCC. These tumors typically originate from
the tonsillar crypts and have a characteristic appearance
described as infiltration of the lymphoid stroma as lob-
ules of immature basaloid cells with minimal cytoplas-
mic keratinization [4].
Routine HPV testing of OPSqCC has expanded the
morphologic spectrum of HPV-related cases. These
histologic variants include papillary, lymphoepithelial-
like, basaloid squamous, and adenosquamous. Although
these phenotypic variations may be diagnostically rele-
vant, they do not appear to impact prognosis. ThePET scan pre-treatment
Fig. 2 Left PET scan pre-treatment. Right PET scan post-treatmentpresence of HPV consistently imparts a favorable prog-
nosis, even when detected in more aggressive pheno-
types such as the basaloid squamous cell carcinoma [5].
For patients with HPV-related cancer of the orophar-
ynx, recognition of the small cell variant and its distinc-
tion from HPV-related squamous cell carcinoma is
important although not straightforward. Both tumor
types share morphologic features that include small
hyperchromatic cells with scant cytoplasm and comedo-
necrosis [6]. Absence of p63 is often used to differentiate
SCLC from squamous cell carcinoma of the lung [7, 8]
yet in one case series 4 of 8 tested oropharyngeal SCCs
were p63 positive suggesting poor reliability of this bio-
marker. Cytokeratin 5/6 on the other hand, seems to be
a more reliable distinguishing marker [2]. In contrast to
OPSqCCs that are consistently cytokeratin 5/6 positive,
all SCCs are cytokeratin 5/6 negative. A minority of oro-
pharyngeal SCC is TTF-1 positive which seems to signify
high specificity for SCC in this setting [9]. In general, all
SCCs demonstrate immunohistochemical evidence of
neuroendocrine differentiation namely synaptophysin
and chromogranin positivity [2]. In the case of SCCs of
the oropharynx, p16 positivity may not be a reliable sur-
rogate marker for HPV infection given that in one study,
2 of 4 SCCs were p16 positive but HPV negative by in-
situ hybridization. This is likely consistent with the find-
ing of p16 positivity in many sites of SCC due to mecha-
nisms unrelated to HPV infection [2, 10].
In SCLC, the most frequently used chemotherapy regi-
men is a platinum (either cisplatin or carboplatin) with
etoposide based upon the clinical activity and toxicity
profile of the platinum agent. Because both agents pos-
sess little mucosal toxicity, limited risk for interstitial
pneumonitis, and modest hematologic toxicity, platinum
plus etoposide is the regimen of choice to use with con-
current chest radiation therapy in patients with limitedPET scan post-treatment
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favorable toxicity profile when used in combination with
external radiation therapy, we decided to use this regi-
men for four cycles with concomitant definitive radi-
ation. The patient’s HPV status did not influence our
treatment decision. We hope that HPV positivity por-
tends a favorable prognosis in this case but from review-
ing the few cases in the literature, it appears that these
patients clinically behave similar to the aggressive nature
of SCLC [11]. Further studies are needed to determine
the pathophysiology of how HPV results in SCC, only
then can potential molecular targets be discovered which
will lead to the development of targeted treatments. In
this patient, the regimen was proven to be active with
manageable toxicities, but longer follow-up will be
needed to determine true efficacy.
In conclusion, patients with HPV-associated cancer of
the oropharynx require an accurate diagnosis to distinguish
the more common squamous cell carcinoma from the rare
small cell variant. This identification is vital in order to
optimize therapy and improve treatment outcomes.
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